Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.04 and traded as low as $6.78. Karyopharm Therapeutics shares last traded at $7.66, with a volume of 233,130 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KPTI shares. HC Wainwright lifted their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, Robert W. Baird decreased their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Karyopharm Therapeutics Price Performance

The company has a market capitalization of $64.50 million, a PE ratio of -7.51 and a beta of 0.11. The firm has a 50-day moving average of $9.54 and a 200 day moving average of $11.04.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. Equities analysts expect that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. raised its stake in shares of Karyopharm Therapeutics by 46.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after buying an additional 2,000,000 shares during the period. GSA Capital Partners LLP grew its position in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after purchasing an additional 792,283 shares in the last quarter. Jane Street Group LLC grew its position in shares of Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after purchasing an additional 543,556 shares in the last quarter. Marshall Wace LLP grew its position in shares of Karyopharm Therapeutics by 15.3% during the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after purchasing an additional 319,187 shares in the last quarter. Finally, Shay Capital LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth about $116,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).